BAP18, as a corepressor of AR together with the SIN3A/HDAC complex, promotes AR-positive triple-negative breast cancer progression
Our study revealed that BAP18, which acts as a novel AR corepressor, is involved in AR-positive TNBC progression, suggesting that BAP18 could be a potential therapeutic target for AR-positive TNBC patients.
Authors
- Y. Li
- T. Zhang (ORCID: https://orcid.org/0000-0002-2231-1593)
- Yiqi Zhang (ORCID: https://orcid.org/0009-0009-3225-413X)
- Zining Jin (ORCID: https://orcid.org/0000-0002-3806-4718)
- Heng Lu (ORCID: https://orcid.org/0000-0001-9775-7824)
- Yue Zhao (ORCID: https://orcid.org/0000-0003-2869-5257)
- Chunyu Wang (ORCID: https://orcid.org/0000-0003-1629-0885)
- Shengli Wang (ORCID: https://orcid.org/0000-0003-2373-072X)
- Xueying Tang (ORCID: https://orcid.org/0000-0002-6172-2512)
- Feng Jin (ORCID: https://orcid.org/0009-0005-3122-6242)
- Ang Zheng (ORCID: https://orcid.org/0000-0003-1078-6660)
- Yi Wu
Institutions
- First Hospital of China Medical University (CN)
- Jinzhou Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Cell & Bioscience
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1186/s13578-025-01489-5
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 0.00